Celularity Inc. Increase (Decrease) in Contract with Customer, Liability
Celularity Inc. (CELU) reported Increase (Decrease) in Contract with Customer, Liability of -$1.09 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-04-30
- Celularity Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$294.00K.
- Celularity Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$914.00K, a 996.08% decline year-over-year.
- Celularity Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-06-30 was $92.00K, a 42.14% decline year-over-year.
- Celularity Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-03-31 was $25.00K, a 50.98% decline year-over-year.
- Celularity Inc. increase (decrease) in contract with customer, liability for fiscal 2025 was -$1.09M, a 564.26% decline from fiscal 2024.
- Celularity Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was $235.00K, a 84.62% decline from fiscal 2023.
- Celularity Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was $1.53M, a 259.53% increase from fiscal 2022.
- Celularity Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was $425.00K.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$294.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | -$1.21M derived: sum of 2 quarters · filed 2026-04-30 | -$1.12M derived: sum of 3 quarters · filed 2026-04-30 | -$1.09M 10-K · filed 2026-04-30 |
| 2025-09-30 | -$914.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$822.00K derived: sum of 2 quarters · filed 2025-11-14 | -$797.00K 10-Q · filed 2025-11-14 | -$874.00K derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-06-30 | $92.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-29 | $117.00K 10-Q · filed 2025-08-29 | $40.00K derived: sum of 3 quarters · filed 2026-04-30 | $142.00K derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-03-31 | $25.00K 10-Q · filed 2025-08-29 | -$52.00K derived: sum of 2 quarters · filed 2026-04-30 | $50.00K derived: sum of 3 quarters · filed 2026-04-30 | $209.00K derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$77.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $25.00K derived: sum of 2 quarters · filed 2026-04-30 | $184.00K derived: sum of 3 quarters · filed 2026-04-30 | $235.00K 10-K · filed 2026-04-30 |
| 2024-09-30 | $102.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $261.00K derived: sum of 2 quarters · filed 2025-11-14 | $312.00K 10-Q · filed 2025-11-14 | $775.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $159.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-29 | $210.00K 10-Q · filed 2025-08-29 | $673.00K derived: sum of 3 quarters · filed 2025-08-29 | $1.56M derived: sum of 4 quarters · filed 2025-08-29 |
| 2024-03-31 | $51.00K 10-Q · filed 2025-08-29 | $514.00K derived: sum of 2 quarters · filed 2025-08-29 | $1.40M derived: sum of 3 quarters · filed 2025-08-29 | $1.55M derived: sum of 4 quarters · filed 2025-08-29 |
| 2023-12-31 | $463.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-08 | $1.35M derived: sum of 2 quarters · filed 2025-05-08 | $1.50M derived: sum of 3 quarters · filed 2025-05-08 | $1.53M 10-K · filed 2025-05-08 |
| 2023-09-30 | $890.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-12-06 | $1.03M derived: sum of 2 quarters · filed 2024-12-06 | $1.06M 10-Q · filed 2024-12-06 | $1.20M derived: sum of 4 quarters · filed 2024-12-06 |
| 2023-06-30 | $143.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | $175.00K 10-Q · filed 2024-11-07 | $306.00K derived: sum of 3 quarters · filed 2024-11-07 | $438.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-03-31 | $32.00K 10-Q · filed 2024-10-16 | $163.00K derived: sum of 2 quarters · filed 2024-10-16 | $295.00K derived: sum of 3 quarters · filed 2024-10-16 | $418.00K derived: sum of 4 quarters · filed 2024-10-16 |
| 2022-12-31 | $131.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $263.00K derived: sum of 2 quarters · filed 2024-07-30 | $386.00K derived: sum of 3 quarters · filed 2024-07-30 | $425.00K 10-K · filed 2024-07-30 |
| 2022-09-30 | $132.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-01-03 | $255.00K derived: sum of 2 quarters · filed 2024-01-03 | $294.00K 10-Q · filed 2024-01-03 | |
| 2022-06-30 | $123.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $162.00K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $39.00K 10-Q · filed 2023-05-22 | |||
| 2021-09-30 | -$7.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$8.04M derived: sum of 2 quarters · filed 2022-11-10 | -$8.63M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$691.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$1.29M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | -$597.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |